TIFA Polyclonal Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
Adapter protein which mediates the IRAK1 and TRAF6 interaction following IL-1 stimulation, resulting in the downstream activation of NF-kappa-B and AP-1 pathways. Induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.
Synonyms
Putative MAPK activating protein PM14; Putative MAPK-activating protein PM14; Putative NF kappa B activating protein 20; Putative NF-kappa-B-activating protein 20; T2BP; TA; TA_HUMAN; TRAF interacting protein with FHA domain containing protein A; TRAF-interacting protein with FHA domain-containing protein A; TRAF2 binding protein; TRAF2-binding protein.
Cellular Locus
Cytoplasm, Nucleus
Host
Rabbit
Cross Reactivity
Mouse
Immunogen
51-150/184
Target
TIFA
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic peptide derived from human TIFA
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Predicted Cross Reactivity
Human, Rat, Dog, Cow, Sheep, Pig, Chicken
More Discoveries
Explore Other Products
Browse additional items from our catalog
